Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 1 results out of 1
Data Insights
Ficlatuzumab by AVEO Pharmaceuticals for Oropharyngeal Cancer: Likelihood of Approval
Ficlatuzumab is under clinical development by AVEO Pharmaceuticals and currently in Phase III for Oropharyngeal Cancer. According to GlobalData, Phase...